You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNatalizumab
Accession NumberDB00108  (BIOD00083, BTD00083)
TypeBiotech
GroupsApproved, Investigational
Description

Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006.

Protein structureDb00108
Protein chemical formulaNot Available
Protein average weightNot Available
Sequences
Synonyms
Anti-alpha4 integrin
Anti-VLA4
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tysabriinjection300 mg/15mLintravenousElan Pharmaceuticals, Inc.2004-11-232016-06-30Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tysabrisolution300 mgintravenousBiogen Canada Inc2006-11-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tysabriinjection300 mg/15mLintravenousBiogen Idec Inc.2004-11-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII3JB47N2Q2P
CAS number189261-10-7
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor treatment of multiple sclerosis.
PharmacodynamicsIn multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain. α4-integrin is required for white blood cells to move into organs, therefore, natalizumab prevents these immune cells from crossing blood vessel walls to reach affected organs thereby decreasing inflamation.
Mechanism of actionBinds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
AbsorptionNot Available
Volume of distribution
  • 5.7 ± 1.9 L [Multiple Sclerosis (MS) Patients]
  • 5.2 ± 2.8 L [Crohn’s Disease (CD) Patients]
Protein bindingNot Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system when bound to leukocytes.

Route of eliminationNot Available
Half life11 ± 4 days
Clearance
  • 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose]
  • 22 +/- 22 mL/hour [Patients with Crohn’s Disease receiving the repeat IV administration of a 300 mg dose]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous300 mg/15mL
Solutionintravenous300 mg
Prices
Unit descriptionCostUnit
Tysabri 300 mg/15 ml vial207.31USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
References
Synthesis ReferenceNot Available
General References
  1. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn’s disease. N Engl J Med. 2003 Jan 2;348(1):24-32. Pubmed
  2. Patent Information Link
External Links
ATC CodesL04AA23
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelDownload (96 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Natalizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.
ado-trastuzumab emtansineThe risk or severity of adverse effects can be increased when ado-trastuzumab emtansine is combined with Natalizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Natalizumab.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Natalizumab.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.
Anti-thymocyte Globulin (Rabbit)The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with Natalizumab.
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Natalizumab.
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Natalizumab.
BasilThe risk or severity of adverse effects can be increased when Basil is combined with Natalizumab.
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Natalizumab.
BelimumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Belimumab.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Natalizumab.
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Natalizumab.
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Natalizumab.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Natalizumab.
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Natalizumab.
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab.
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Natalizumab.
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Natalizumab.
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Natalizumab.
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Natalizumab.
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Natalizumab.
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Natalizumab.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Natalizumab.
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Natalizumab.
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Natalizumab.
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Natalizumab.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Natalizumab.
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Natalizumab.
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Natalizumab.
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Natalizumab.
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Natalizumab.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Natalizumab.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Natalizumab.
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Natalizumab.
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Natalizumab.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab.
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Natalizumab.
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Natalizumab.
golimumabThe risk or severity of adverse effects can be increased when golimumab is combined with Natalizumab.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Natalizumab.
IbritumomabThe risk or severity of adverse effects can be increased when Ibritumomab is combined with Natalizumab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Natalizumab.
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab.
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Natalizumab.
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Natalizumab.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Natalizumab.
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Natalizumab.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Natalizumab.
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Natalizumab.
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Natalizumab.
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Natalizumab.
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Natalizumab.
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Natalizumab.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Natalizumab.
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.
OsimertinibThe risk or severity of adverse effects can be increased when Osimertinib is combined with Natalizumab.
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Natalizumab.
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Natalizumab.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with Natalizumab.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Natalizumab.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Natalizumab.
Repository corticotropinThe risk or severity of adverse effects can be increased when Repository corticotropin is combined with Natalizumab.
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Natalizumab.
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.
RoflumilastRoflumilast may increase the immunosuppressive activities of Natalizumab.
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Natalizumab.
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with Natalizumab.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Natalizumab.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Natalizumab.
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Natalizumab.
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Natalizumab.
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Natalizumab.
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Natalizumab.
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.
TofacitinibNatalizumab may increase the immunosuppressive activities of Tofacitinib.
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Natalizumab.
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Natalizumab.
TrastuzumabTrastuzumab may increase the neutropenic activities of Natalizumab.
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Natalizumab.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Natalizumab.
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Natalizumab.
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Natalizumab.
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Natalizumab.
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Natalizumab.
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Natalizumab.
Food InteractionsNot Available

Targets

1. Integrin alpha-4

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antibody

Components

Name UniProt ID Details
Integrin alpha-4 P13612 Details

References:

  1. Sheremata WA, Minagar A, Alexander JS, Vollmer T: The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. CNS Drugs. 2005;19(11):909-22. Pubmed
  2. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guerette C, Antel JP, Fournier A, Grand’Maison F, Bar-Or A: Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006 May;59(5):748-54. Pubmed
  3. Stuve O, Bennett JL: Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 2007 Spring;13(1):79-95. Pubmed
  4. Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T: Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood. 1997 Dec 15;90(12):4779-88. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Low affinity immunoglobulin gamma Fc region receptor III-B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor III-B O75015 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

3. Complement C1r subcomponent

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1r subcomponent P00736 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Complement C1q subcomponent subunit A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1q subcomponent subunit A P02745 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

5. Complement C1q subcomponent subunit B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1q subcomponent subunit B P02746 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

6. Complement C1q subcomponent subunit C

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1q subcomponent subunit C P02747 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

7. Low affinity immunoglobulin gamma Fc region receptor III-A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor III-A P08637 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

8. High affinity immunoglobulin gamma Fc receptor I

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
High affinity immunoglobulin gamma Fc receptor I P12314 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

9. Low affinity immunoglobulin gamma Fc region receptor II-a

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor II-a P12318 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

10. Low affinity immunoglobulin gamma Fc region receptor II-b

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor II-b P31994 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

11. Low affinity immunoglobulin gamma Fc region receptor II-c

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor II-c P31995 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

12. Intercellular adhesion molecule 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Intercellular adhesion molecule 1 P05362 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2010 14:34